Ophthalmic Therapeutic Innovation

Executive Summary

Ophthalmic Therapeutic Innovation (OTI) is a privately held biotechnology company headquartered in Cambridge, MA, focused on developing first-in-class small molecule therapies for glaucoma. Founded in 2018, OTI's lead candidate, OTI-2024, is a dual adenosine receptor modulator and matrix metalloproteinase (MMP) agent designed to address the root causes of glaucoma by normalizing intraocular pressure (IOP) and promoting tissue rejuvenation. The company's mission is to redefine glaucoma care beyond symptomatic IOP reduction, targeting disease modification and ocular tissue repair. OTI operates in the competitive ophthalmic space, with a novel mechanism that could differentiate it from existing therapies such as prostaglandin analogs and Rho kinase inhibitors. OTI is currently advancing OTI-2024 through preclinical and early clinical development. While limited public information is available on the compound's safety and efficacy profile, the adenosine and MMP pathways represent an innovative approach to glaucoma treatment. Key risks include the early stage of development, lack of published clinical data, and the challenges of demonstrating disease-modifying effects in a chronic condition. Upcoming catalysts include initiation of first-in-human studies and potential regulatory milestones. If successful, OTI-2024 could offer a paradigm shift in glaucoma management, though significant clinical and regulatory hurdles remain.

Upcoming Catalysts (preview)

• Q2 2026Initiation of Phase 1 Clinical Trial for OTI-202460% success
• Q4 2026Topline Phase 1 Safety and Tolerability Data50% success
• Q3 2026Orphan Drug Designation from FDA for Glaucoma70% success